Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicostop is a non-specific product name used for more than one smoking-cessation product rather than a single well-defined drug. In the provided context, it refers at least to a nicotine-containing smoking-cessation pharmaceutical marketed as Nicostop-Mepha for relief of nicotine withdrawal and cigarette dependence, and separately to a French homeopathic tablet product containing lycopodium, staphysagria, lobelia, and tobaccum that is promoted for reducing tobacco craving. Because these products differ in active ingredients, mechanism, developer, and regulatory character, Nicostop should be treated as an ambiguous name unless a manufacturer or formulation is specified.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nicostop.